Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J. Motzer, Theodore Stewart Gourdin, Masatoshi Eto et al.|Journal of Clinical Oncology|2024Cited by 170